The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia (Q36849336)

16 August 2017

1 reference

title

The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia (English)

1 reference

16 August 2017

0 references

1 reference

Kay NE

1

1 reference

16 August 2017

O'Brien SM

series ordinal

2

1 reference

16 August 2017

Pettitt AR

series ordinal

3

1 reference

16 August 2017

Stilgenbauer S

series ordinal

4

1 reference

16 August 2017

publication date

14 June 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

21

1 reference

16 August 2017

issue

9

1 reference

16 August 2017

page(s)

1885-1891

1 reference

Chronic lymphocytic leukemia

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

A clinical staging system for chronic lymphocytic leukemia: prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Risk stratification in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of UnmutatedVHGene in Patients With Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Clinical significance of CD38 expression in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Update on risk-stratified management for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404802

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404802

1 reference

release_n3wiebz67zcxllghng26qgm2dq

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/n3wiebz67zcxllghng26qgm2dq

24 November 2022

mapped directly with Wikidata item

1 reference